-
2 weeks ago | 
medscape.com | Ted Bosworth
CHICAGO — A transcatheter aortic valve implantation (TAVI) device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in an expansion cohort of the ALIGN-AR trial, paving the way for a randomized trial in lower-risk patients.
-
2 weeks ago | 
portugues.medscape.com | Ted Bosworth
Estados Unidos — Em idosos com alto risco de insuficiência cardíaca e indicação para implante transcateter de válvula aórtica (transcatheter aortic valve implantation, TAVI), a dapagliflozina, um inibidor do cotransportador de sódio-glicose tipo 2 (SGLT2), reduziu o risco de morte e eventos de insuficiência cardíaca em quase 30%, segundo o estudo randomizado DapaTAVI.
-
2 weeks ago | 
medscape.com | Ted Bosworth
CHICAGO — The remarkable and sustained reductions in lipoprotein(a) ( Lp[a]) achieved with lepodisiran (Eli Lilly) , a novel small-interfering (si)RNA molecule, in a phase 2 trial might signal a major leap forward in the management of residual cardiovascular risk if the expected therapeutic benefit is confirmed in ongoing trials.
-
2 weeks ago | 
deutsch.medscape.com | Ted Bosworth
Chicago – Bei Patienten mit Typ-2-Diabetes, die eine manifeste atherosklerotische Herz-Kreislauf-Erkrankung, eine chronische Nierenerkrankung oder beides haben, senkt orales Semaglutid das Risiko für schwerwiegende kardiovaskuläre Ereignisse. Das zeigen Ergebnisse der SOUL-Studie, einer internationalen, placebokontrollierten Phase-3b-Studie.
-
2 weeks ago | 
medscape.com | Ted Bosworth
ORLANDO, Fla. — Beyond appropriate use criteria for Mohs surgery outlined by a multidisciplinary ad hoc task force in 2012, choice of treatment for superficial skin cancers like basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in situ remains highly individualized, according to a Mohs surgeon who spoke at the American Academy of Dermatology (AAD) 2025 Annual Meeting. Simply stated, “Mohs is not always the best option,” said Abigail H.
-
3 weeks ago | 
medscape.com | Ted Bosworth
CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, reduces the risk for death and heart failure events by almost 30%, the randomized DapaTAVI trial shows.
-
3 weeks ago | 
medscape.com | Ted Bosworth
ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival biologics. In one, a 75% skin clearance on the Psoriasis Area Severity Index (PASI) was achieved with a drug currently known as ICP-488 in nearly 80% of patients by week 12.
-
3 weeks ago | 
medscape.com | Ted Bosworth
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous lupus erythematosus (CLE). Unlike an earlier study, which was restricted to patients with systemic lupus erythematosus (SLE), the most recent trial enrolled patients with the most common forms of CLE, which are discoid lupus erythematosus (DLE) and the subacute form of CLE (SCLE), reported Victoria P.
-
3 weeks ago | 
medscape.com | Ted Bosworth
CHICAGO — In patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral formulation of semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, reduces the risk for major adverse cardiovascular events, according to SOUL, an international phase 3b placebo-controlled trial.
-
1 month ago | 
medscape.com | Ted Bosworth
ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early and in relatively high doses, according to two sets of research. “There are now a lot of clinicians and researchers in psoriasis who believe that IL-23 inhibitors are unique relative to other biologics,” explained Anthony P.
